PTC Therapeutics IncNASDAQ:PTCT
- LAST PRICE43.8800
- TODAY'S CHANGE (%)-1.2300 (-2.7267%)
- Bid / Lots42.8500/ 1
- Ask / Lots45.6500/ 1
- Open / Previous Close44.7700 / 45.1100
- Day Range
- 52 Week Range
- Volume428,781
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PTCT |
|---|---|---|
| 09:32 ET | 3810 | 44.77 |
| 09:33 ET | 640 | 44.81 |
| 09:35 ET | 9091 | 44.71 |
| 09:37 ET | 300 | 44.4 |
| 09:42 ET | 300 | 44.24 |
| 09:44 ET | 3401 | 43.79 |
| 09:46 ET | 200 | 43.835 |
| 09:48 ET | 100 | 43.71 |
| 09:50 ET | 4091 | 43.85 |
| 09:51 ET | 1150 | 43.7 |
| 09:53 ET | 800 | 43.45 |
| 09:55 ET | 450 | 43.35 |
| 09:57 ET | 778 | 43.19 |
| 10:00 ET | 3446 | 43.235 |
| 10:02 ET | 1200 | 43.71 |
| 10:04 ET | 7120 | 44.19 |
| 10:06 ET | 1786 | 44.18 |
| 10:08 ET | 1052 | 44.17 |
| 10:09 ET | 500 | 44.08 |
| 10:11 ET | 13785 | 44.16 |
| 10:13 ET | 4000 | 44.13 |
| 10:15 ET | 5869 | 43.98 |
| 10:18 ET | 500 | 43.82 |
| 10:20 ET | 933 | 44.08 |
| 10:22 ET | 2626 | 43.94 |
| 10:26 ET | 4288 | 44 |
| 10:27 ET | 6000 | 43.85 |
| 10:29 ET | 200 | 43.775 |
| 10:31 ET | 2128 | 43.94 |
| 10:33 ET | 405 | 43.995 |
| 10:36 ET | 700 | 43.92 |
| 10:38 ET | 400 | 43.75 |
| 10:40 ET | 1800 | 43.78 |
| 10:42 ET | 400 | 43.835 |
| 10:44 ET | 500 | 43.905 |
| 10:45 ET | 8992 | 44.08 |
| 10:47 ET | 1862 | 44 |
| 10:51 ET | 1593 | 43.905 |
| 10:54 ET | 200 | 43.805 |
| 10:56 ET | 500 | 43.65 |
| 10:58 ET | 100 | 43.665 |
| 11:00 ET | 1599 | 43.75 |
| 11:02 ET | 400 | 43.715 |
| 11:03 ET | 143 | 43.735 |
| 11:05 ET | 600 | 43.7 |
| 11:09 ET | 100 | 43.61 |
| 11:12 ET | 2175 | 43.735 |
| 11:14 ET | 500 | 43.68 |
| 11:16 ET | 800 | 43.58 |
| 11:18 ET | 1636 | 43.6 |
| 11:20 ET | 1757 | 43.39 |
| 11:21 ET | 100 | 43.435 |
| 11:23 ET | 300 | 43.42 |
| 11:25 ET | 1340 | 43.53 |
| 11:27 ET | 100 | 43.52 |
| 11:30 ET | 701 | 43.4201 |
| 11:32 ET | 912 | 43.42 |
| 11:34 ET | 100 | 43.425 |
| 11:36 ET | 100 | 43.425 |
| 11:38 ET | 535 | 43.425 |
| 11:39 ET | 3480 | 43.385 |
| 11:41 ET | 500 | 43.385 |
| 11:43 ET | 1417 | 43.4376 |
| 11:45 ET | 300 | 43.43 |
| 11:48 ET | 953 | 43.4 |
| 11:50 ET | 848 | 43.4 |
| 11:52 ET | 3694 | 43.45 |
| 11:54 ET | 1355 | 43.5 |
| 11:56 ET | 500 | 43.45 |
| 11:57 ET | 1267 | 43.475 |
| 11:59 ET | 2064 | 43.37 |
| 12:01 ET | 400 | 43.37 |
| 12:03 ET | 400 | 43.31 |
| 12:06 ET | 3038 | 43.37 |
| 12:08 ET | 300 | 43.38 |
| 12:10 ET | 329 | 43.42 |
| 12:12 ET | 300 | 43.44 |
| 12:14 ET | 862 | 43.425 |
| 12:15 ET | 4584 | 43.4645 |
| 12:17 ET | 100 | 43.46 |
| 12:19 ET | 100 | 43.44 |
| 12:21 ET | 2476 | 43.505 |
| 12:24 ET | 2712 | 43.62 |
| 12:28 ET | 500 | 43.605 |
| 12:30 ET | 200 | 43.605 |
| 12:32 ET | 2905 | 43.65 |
| 12:33 ET | 700 | 43.67 |
| 12:35 ET | 9070 | 43.87 |
| 12:39 ET | 4509 | 43.88 |
| 12:42 ET | 3428 | 43.8 |
| 12:44 ET | 1300 | 43.82 |
| 12:46 ET | 5331 | 43.95 |
| 12:48 ET | 1446 | 43.92 |
| 12:50 ET | 4919 | 43.97 |
| 12:51 ET | 5515 | 43.975 |
| 12:53 ET | 3343 | 44.01 |
| 12:55 ET | 4321 | 43.77 |
| 12:57 ET | 3655 | 43.87 |
| 01:00 ET | 84365 | 43.88 |
Nov 27, 2024
DJ PTC Therapeutics Is Maintained at Outperform by Baird, from 8:19AM ET on Wednesday Nov 27, 2024 by Dow Jones
8:19AM ET on Wednesday Nov 27, 2024 by Dow JonesPTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million, from 7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 26, 2024
DJ PTC Therapeutics to End Development of ALS Treatment, from 5:06PM ET on Tuesday Nov 26, 2024 by Dow Jones
5:06PM ET on Tuesday Nov 26, 2024 by Dow JonesPTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients, from 4:30PM ET on Tuesday Nov 26, 2024 by Dow Jones
4:30PM ET on Tuesday Nov 26, 2024 by Dow JonesDJ PTC Therapeutics Is Maintained at Overweight by Wells Fargo, from 8:08AM ET on Tuesday Nov 26, 2024 by Dow Jones
8:08AM ET on Tuesday Nov 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PTC Therapeutics Inc | 3.5B | -7.4x | --- |
HUTCHMED (China) Ltd | 3.1B | -67.9x | --- |
Prestige Consumer Healthcare Inc | 4.2B | 20.7x | --- |
Amphastar Pharmaceuticals Inc | 2.1B | 15.0x | --- |
Tilray Brands Inc | 1.2B | -4.9x | --- |
Harmony Biosciences Holdings Inc | 2.0B | 16.4x | --- |
Company Information
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Contact Information
- Headquarters
- 500 Warren Corporate Center DriveWARREN, NJ, United States 07059
- Phone
- 908-222-7000
- Fax
- 908-222-7231
Executives
- Independent Chairman of the Board
- Michael Schmertzler
- President, Chief Executive Officer, Director
- Matthew Klein
- Chief Financial Officer
- Pierre Gravier
- Chief Technical Operations Officer
- Neil Almstead
- Executive Vice President, Chief Legal Officer
- Mark Boulding
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.5B |
|---|---|
Revenue (TTM) | $900.7M |
Shares Outstanding | 77.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.64 |
EPS | $-5.94 |
Book Value | $-10.81 |
P/E Ratio | -7.4x |
Price/Sales (TTM) | 3.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -30.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
